Search Results - "Mourey L"

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update.

Authors: Mourey, L. Conter, H.J. Shore, N. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS516-S517. 2p.

This result is not displayed to guests.
Login for full access.

898PVOTRAGE study pazopanib in a population of "frail" elderly patients after geriatric assessment: A phase I study with geriatric criteria.

Authors: Mourey, L Ravaud, A Digue, L et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

Unité Pilote de Coordination en Oncogériatrie (UPCOG) Midi-Pyrénées: 1 year results elderly cancer patients, where do they come from?

Authors: Mourey, L. Gerard, S. Balardy, L. et al.

Source: Critical Reviews in Oncology/Hematology. Oct2008 Supplement 2, Vol. 68, pS34-S34. 1p.

Robot-assisted post-chemotherapy retroperitoneal lymph node dissection in germ cell tumor: is the single-docking with lateral approach relevant?

Authors: Overs, C. Beauval, J. B. Mourey, L. et al.

Source: World Journal of Urology. Apr2018, Vol. 36 Issue 4, p655-661. 7p.

Vinflunine oral pharmacokinetics and absolute bioavailability of soft and hard gelatin capsules: results of two phase I trials.

Authors: Delord JP Bennouna J Mourey L et al.

Source: Clinical Pharmacokinetics. 2012, Vol. 51 Issue 6, p357-364. 8p.

670P Cabozantinib associated with concomitant radiotherapy or a bone targeted agent (multimodal approach, results from the CABOREAL study post-hoc analysis).

Authors: Gross-Goupil, M. Fléchon, A. Mourey, L. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS694-S695. 2p.

722P Cabozantinib in elderly patients: Results from a subanalysis of the CABOREAL study.

Authors: Gross-Goupil, M. Fléchon, A. Mourey, L. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS566-S567. 2p.

2817P Development of a care complexity score to predict severe adverse events (PRO-CTCAE) and resource utilization in remote patient monitoring for oncology: Analysis from 5,625 patients across 86 sites.

Authors: Franzoi, M.A. Baldini, C. Grellety, T. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1496-S1496. 1p.

Distinction between pore assembly by staphylococcal alpha-toxin versus leukotoxins.

Authors: Joubert O Voegelin J Guillet V et al.

Source: Journal of Biomedicine & Biotechnology. 2007 Regular Issue, p1-13. 13p.

URL: 28142539

1907P Deployment of remote patient monitoring in older patients: A real-world experience from 2419 patients across 58 centres in France and Belgium.

Authors: Bertrand, N. Grellety, T. Autheman, M. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1111-S1112. 2p.

Further insights into the mechanism of function of the response regulator CheY from crystallographic studies of the CheY--CheA124--257 complex.

Authors: Gouet, P. Chinardet, N. Welch, M. et al.

Source: Acta Crystallographica: Section D (Wiley-Blackwell). Jan2001, Vol. 57 Issue 1, p44-51. 8p.

Subjects: Crystallography, Phosphorylation, Chemical reactions, Ferromagnetic materials, Magnetic domain, Crystals, Physical sciences

Multidisciplinary development of the Geriatric Core Dataset for clinical research in older patients with cancer: A French initiative with international survey.

Authors: Paillaud, E. Soubeyran, P. Caillet, P. et al.

Source: European Journal of Cancer. Nov2018, Vol. 103, p61-68. 8p.

1837P Assessing care complexity in remote patient monitoring (RPM): A cohort study of 2434 cancer patients across 50 sites in France and Belgium.

Authors: Baldini, C. Grellety, T. Boulahssass, R. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1086-S1086. 1p.

1651P Characteristics, tolerance and effectiveness of patients aged more or less than 75 years treated with [177Lu]Lu-PSMA-617 as part of France's early access program.

Authors: Tonnelet, D. Farce, J. Agrigoroaie, L. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS995-S995. 1p.

1627P Long survivors after androgen deprivation therapy (ADT) with or without docetaxel for metastatic castration-sensitive prostate cancer (mCSPC): Long-term follow-up of GETUG-15.

Authors: Blanchet-Deverly, S. Fizazi, K. Oudard, S. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS982-S982. 1p.

1595MO Phenotypic and genomic characterization of de novo metastatic prostate cancer: An ancillary study of the PEACE-1 phase III trial.

Authors: Pobel, C. Bargain, C. Scoazec, J. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS962-S962. 1p.

PE94 - Feasibility and safety of lateral approach with single-docking robotic post chemotherapy modified retroperitoneal lymph node dissection in germ cell tumor.

Authors: Overs, C. Beauval, J.-B. Mourey, L. et al.

Source: European Urology Supplements. Sep2017, Vol. 16 Issue 6, pe2366-e2366. 1p.